Digital pathology system helps pathologists review slides
Official title: Clinical Study Protocol SGi 1.0 + EPW 1.0 + Compatible Clinical Displays Clinical Validation Study
Run by Philips Digital & Computational Pathology · NCT07881874 · Data updated 2026-11-12
A digital pathology system is being tested to see if it safely and accurately helps pathologists view and diagnose digital slides from surgical pathology samples.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 470 (estimated) |
| Sponsor | Philips Digital & Computational Pathology Industry-sponsored |
| Locations | 2 sites (San Francisco, California and 1 other locations) |
| Status | Recruiting |
| Started | August 1, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | January 15, 2027 |
| Registry record updated | October 22, 2026 |
| Trial ID | NCT07881874 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are pathology sites with archived surgical pathology slides (H&E, IHC, and special stains) and available original sign-out diagnoses from a year or more ago.
✕Probably not a fit
Patients with cases lacking original slides, control slides, or with inadequate slide quality may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates a digital pathology platform (SGi 1.0 + EPW 1.0 with compatible displays) used as an aid for pathologists reviewing surgical pathology slides. The study uses existing glass slides (H&E, IHC, and special stains) and related clinical information to compare the system's performance with historical signs-out diagnoses. Cases are at least one year old and must have complete archival slides and control materials available. The trial is led by Philips Digital & Computational Pathology with collaboration from UCSF and CCPL. Patient impact focuses on diagnostic workflow rather than a direct patient treatment.
Why it matters
Potential benefit: If successful, the system could streamline pathology review and support more consistent diagnoses.
How similar studies have gone: Similar digital pathology validation studies have shown potential benefits in diagnostic workflow, though results can vary by setup and tissue type.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All hematoxylin and eosin (H\&E), immunohistochemistry (IHC) and special stains glass coverslipped slide or slides, with human tissue obtained via surgical pathology of original case are available; * Original sign-out diagnosis is available; * Relevant clinical information that was available to the sign-out pathologist in the pathology request form is available; * Cases are at least one year since accessioning; Exclusion Criteria: * Cases, including sent out cases, for which the selected (representative) H\&E, IHC or special stains slide used for the original sign-out diagnosis is no longer available at the site. * Cases for which the control slides for IHC and special stains are not available. * The selected slide or slides for the main diagnosis and the control slide(s) do not fulfill the quality checks according to general clinical practice. * Selected (representative) slides contain indelible markings. * Selected (representative) slides with damaged tissue.
Where it's running
-
UCSF
San Francisco, California, United States Recruiting -
Ccpl
Silver Spring, Maryland, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preventing liver complications after TIPS placement with rifaximin and lactulose
This study is testing if taking rifaximin and lactulose can help prevent brain problems in adults with liver cirrhosis after they have a procedure called TIPS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.